<DOC>
	<DOCNO>NCT02262169</DOCNO>
	<brief_summary>This 2-arm , prospective , double-blind , double-dummy , randomized-controlled study use DLBS2411 dose 250 mg twice daily ( morning evening meal ) , omeprazole dose 40 mg daily ( morning meal ) , 8-week course therapy , treatment patient non-bleeding peptic ulcer . DLBS2411 bioactive fraction Indonesian native herbal , Cinnamomum burmanii , locally know kayu manis proven cellular genetic level antiulcer effect suppress gastric acidity enhance gastric mucosal protection . The anti-secretory effect DLBS2411 exert inhibition H+/K+ ATPase 'pump ' well down-regulation H+/K+ ATPase gene expression , thus suppress gastric acid secretion ; gastro-protective defense mechanism work promotion COX-2 derive prostaglandin ( PgE2 ) synthesis , stimulate gastric-epithelial mucous bicarbonate secretion ; anti-oxidative activity ; endothelial-nitric oxide ( NO ) formation . Recent study DLBS2411 healthy volunteer demonstrate effective role safety DLBS2411 suppress intragastric acidity . Having mechanisms action , DLBS2411 hypothesize benefit peptic ulcer .</brief_summary>
	<brief_title>DLBS2411 Treatment Ulcer Healing Non-Bleeding Peptic Ulcers</brief_title>
	<detailed_description>A total 140 subject allocate 2 group treatment ; group consist 70 subject treatment regimens : Treatment I : 2 capsule Omeprazole 20 mg , daily 1 placebo caplet DLBS2411 , twice daily Treatment II : 1 caplet DLBS2411 250 mg , twice daily 2 placebo capsule omeprazole , daily DLBS2411 administer twice daily least 30 minute morning evening meal , omeprazole , daily morning meal , 8 week study period . The eligible subject receive either study medication ( Treatment 1 Treatment 2 ) , 8 week treatment ; instruct come clinic every 4-week interval throughout study period . Subjects evaluate treatment efficacy baseline interval 4 week 8-week course therapy . The safety profile study medication vital sign adverse event measure baseline end study . Vital sign adverse event measure baseline every follow-up visit include end study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Male female subject age 1875 year old . Diagnosed nonbleeding peptic ulcer require endoscopic therapy , confirm : The presence endoscopically confirm gastric duodenal ulcer ( ) size ( ) least 3 mm large . Subjects lowrisk recurrent bleeding , define : Complete Rockall score â‰¤ 7 . Endoscopic stigma ( lesion ) grade IIC III base Forrest classification . Able take oral medication . For female childbearing potential : pregnancy , breastfeeding , intention become pregnant study participation . Patients must accept pregnancy test trial menstrual cycle miss Fertile patient must use reliable effective contraceptive History know suspect Zollinger Ellison syndrome . History endoscopic therapy bleed ulcer within past 4 week . Indication endoscopic hemostasis therapy . Presence Helicobacter pylorus infection identify serologic test . History known coronary artery disease ( CAD ) , congestive heart failure , pulmonary disease , uncontrolled chronic disease . History known gastrointestinal malignancy ulcer associate malignancy . Currently know afflict serious infection ( ) . Inadequate liver function Inadequate renal function Subjects therapy herbal medicine . Known hypersensitivity idiosyncratic reaction adverse drug reaction proton pump inhibitor ( PPIs ) . Participation clinical study within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Non-Bleeding Peptic Ulcers , DLBS2411 , Ulcer Healing</keyword>
</DOC>